Despite that, he was very pleased with Pacific Edge’s growth, particularly its revenue and total laboratory throughput increases. He was comfortable with its loss increase, of around $5.9 million, because the company had taken a long-term approach with research and innovation, Dr Meintjes said. While the impact of Covid on Pacific Edge’s sales had been "very real", the company had been able to grow while others had not, he said. Pacific Edge’s sales team would be able to resume meeting customers in person, attend conferences and key speaking engagements. Following the company’s results announcement, Pacific Edge’s share price on the NZX fell more than 7% to 77c.

Source: Otago Daily Times May 26, 2022 19:29 UTC